Bank of New York Mellon Corp Cuts Position in Intuitive Surgical, Inc. $ISRG

Bank of New York Mellon Corp trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,550,375 shares of the medical equipment provider’s stock after selling 369,852 shares during the period. Bank of New York Mellon Corp’s holdings in Intuitive Surgical were worth $1,636,688,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ISRG. Holos Integrated Wealth LLC bought a new position in Intuitive Surgical in the fourth quarter worth about $25,000. Newbridge Financial Services Group Inc. lifted its position in shares of Intuitive Surgical by 300.0% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 44 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 33 shares during the last quarter. Olistico Wealth LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $28,000. Laurel Wealth Advisors LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $31,000. Finally, Vermillion Wealth Management Inc. grew its position in shares of Intuitive Surgical by 58.1% in the 1st quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 25 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: BMO Capital initiated coverage with an Outperform rating, adding to the case that Intuitive Surgical can continue to defend its leadership in robotic surgery. BMO Capital Starts Intuitive Surgical (ISRG) at Outperform
• Positive Sentiment: Several articles note that ISRG heads into earnings with strong procedure momentum, da Vinci 5 adoption, and a history of beating estimates, which supports hopes for another solid quarter. Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
• Positive Sentiment: Intuitive Surgical’s Ion lung biopsy study is approaching a data readout, highlighting a potential new growth avenue beyond core robotic surgery. Intuitive Surgical’s Ion Lung Biopsy Study Nears Data Readout, Eyeing New Growth in Diagnostics
• Neutral Sentiment: Commentary around Intuitive Surgical’s leadership versus rising global competition is mixed: the company is using AI features and a broad ecosystem to defend share, but competition remains a watch item. Can ISRG Defend Its Leadership as Global Competition Intensifies?
• Neutral Sentiment: Some coverage frames the move as a pre-earnings repositioning event, with investors weighing recent analyst target cuts, margin pressure from tariffs, and broader medical-device weakness more than any new company-specific setback. Intuitive Surgical Falls as Target Cut and Pre-Earnings Jitters Weigh on Shares

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ISRG shares. TD Cowen decreased their target price on shares of Intuitive Surgical from $585.00 to $520.00 and set a “buy” rating for the company in a research report on Monday. Stifel Nicolaus set a $670.00 price target on shares of Intuitive Surgical in a report on Tuesday. BTIG Research set a $512.00 price target on Intuitive Surgical in a research report on Monday. Leerink Partners decreased their price objective on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Finally, Royal Bank Of Canada lowered their price objective on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $565.31.

Intuitive Surgical Trading Up 2.5%

NASDAQ ISRG opened at $388.97 on Thursday. Intuitive Surgical, Inc. has a 12-month low of $378.50 and a 12-month high of $603.88. The company has a fifty day simple moving average of $418.39 and a two-hundred day simple moving average of $469.98. The stock has a market cap of $137.76 billion, a P/E ratio of 47.15, a P/E/G ratio of 3.09 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same period in the previous year, the company earned $1.81 earnings per share. The business’s quarterly revenue was up 23.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Iman Jeddi sold 5,625 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the sale, the senior vice president owned 6,463 shares in the company, valued at approximately $2,718,014.65. The trade was a 46.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of the stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $463.50, for a total value of $55,156.50. Following the completion of the transaction, the director directly owned 120 shares in the company, valued at $55,620. This represents a 49.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 7,169 shares of company stock worth $3,059,135. 0.60% of the stock is currently owned by insiders.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.